JDRF T1D Fund
Impact investorBoston · Seed–Late Stage · 27 people tracked
Investment thesis
The T1D Fund deploys catalytic capital and scientific expertise to accelerate treatments and cures for type 1 diabetes. It positions itself as a collaboration platform that de-risks investments to draw additional investors into the T1D space, creating a flywheel effect. The fund partners with innovators advancing disease-modifying therapies and reinvests all returns to sustain a continuous cycle that funds foundational research and program development. Its team combines venture, investment banking, pharmaceutical, company-building, and business development experience, and it manages an active portfolio of more than 25 companies focused on curing and treating T1D.
Source: firm website, verified Aug 3, 2026.
Team · 27 people
from the firm's website & public directories
What they invest in
from 22 of 28 portfolio companiesBiotech ×21Medical Devices ×15Healthtech ×10Digital Health ×5Deep Tech ×3AI & Machine Learning ×2
HQs:United States×7France×2
Investments · 28 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 23 dated
BiotechAbingdon, Oxfordshire
Brian Di Donato(Chief Financial Officer)John Bell(Chairman of the Board of Directors)Robert Perez(Director)David Berman(Head of Research and Development)Tina St. Leger(Chief Human Resources Officer)Peter Ratcliffe(Director)
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.
BiotechDigital HealthMedical DevicesHigh Point, US
Rudy Howard(Executive Officer)Paul Meister(Director)Stephen Holcombe(Executive Officer)Paul Savas(Director)Noel Spiegel(Director)Howard Weiner(Director)
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical Devices
Akin Akinc, Ph.D.(CEO)
Aspect Bio Systems develops bioprinted tissue therapeutics for regenerative medicine using a platform that combines AI-powered bioprinting, computational design, therapeutic cells, and biomaterials.
AI & Machine LearningBiotechDeep Tech
Digital HealthHealthtechMedical DevicesNew York, US
Jeffrey Brewer(Executive Officer, Director)Bryan Mazlish(Executive Officer, Director)Jon Brilliant(Executive Officer)
Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.
BiotechDigital HealthHealthtechMedical DevicesSan Diego, US
Richard Yang(Executive Officer, Director)Edward Kliphuis(Director)Jared Tangney(Executive Officer, Director, Promoter)
BoardDaniel Bradbury(Director)Lana Ghanem(Director)
COUR develops targeted therapies for autoimmune diseases using an antigen-specific platform technology designed to restore immune tolerance while preserving normal immune function.
BiotechHealthtechMedical Devices
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)Jean-Pascal Tranié(Co-Founder)
Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers.
Biotech
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical Devices
Biopharmaceutical gene therapy company developing gene therapies intended to be accessible broadly rather than to a limited few.
BiotechMorrisville, US
Ilan Oren(Director)Shankar Ramaswamy(Executive Officer, Director)Michele Stone(Executive Officer)Katherine Eade(Executive Officer)Britt Petty(Executive Officer)Daniel Chen(Executive Officer)
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Sanofi develops breakthrough medicines and vaccines by applying deep understanding of the immune system.
BiotechHealthtechMedical Devices
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Steve Harr(President and Chief Executive Officer)
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Fan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)Jeffrey Bluestone(Executive Officer, Director, Promoter)
Biotech
Exits · 2
IPOs and acquisitions across the tracked portfolioImmunocoreNASDAQ: IMCRVtvtherapeuticsNASDAQ: VTVT
Portfolio news
latest coverage across their companiesSana Biotechnology · simplywall.st · Jul 8, 2026
Jaguar Gene Therapy · clinicaltrialsarena.com · Feb 25, 2026
Mozart Therapeutics · nasdaqprivatemarket.com · Jun 27, 2025
Frequently asked questions
- What stage does JDRF T1D Fund invest at?
- JDRF T1D Fund invests at the Seed, Series A, Series B, Late Stage stages.
- What sectors does JDRF T1D Fund focus on?
- JDRF T1D Fund focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is JDRF T1D Fund located?
- JDRF T1D Fund is headquartered in Boston, US.
Images
Co-investors · 7
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Domain Associates (DomainVC) is a life sciences venture capital firm that served as investment advisors to the first VC fund dedicated to biotech and as investment manager of nine subsequent biotech VC funds.
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
Cultivian Sandbox Ventures is a venture capital firm investing in innovative food and agriculture companies that commercialize solutions across the food and agriculture value chain.
Firms observed investing alongside JDRF T1D Fund, from public investor directories. Shared companies are the overlap with JDRF T1D Fund's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Gilde Healthcare is a specialist investment firm managing healthcare and climate-focused funds across venture & growth, and private equity strategies with a transatlantic team of sector specialists.
Syridex Bio identifies emerging areas of science and medicine to invest in innovations addressing unmet medical needs, applying a health-equity lens to opportunities that can improve outcomes across diverse patient populations.